ACCESS25

The Future of Precision Medicine Starts at the Moment of Diagnosis

OCTOBER 28, 2025 | 11:30AM ET | VIRTUAL EVENT
Join Access25 on October 28 to discover how Proscia is removing one of the biggest barriers to realizing precision medicine — access to the right patients, at the right moment, with the right data.

With the launch of Proscia Aperture™, biopharma leaders will discover how to automatically identify trial and treatment candidates at the moment of diagnosis—accelerating recruitment and advancing novel therapies.

Clinical lab leaders will learn how Aperture elevates the lab’s strategic role in the precision medicine ecosystem while creating new revenue streams.

And for everyone attending, the Partner Expo will feature breakthroughs in pathology AI, next-generation infrastructure, and enterprise solutions—delivered by the strongest ecosystem in the industry.

Register for Access25 today to secure your spot.

Read on for more information about the event, including segmented tracks for Aperture, and Partner Expo sessions:

Join Us at Access25

Aperture Logo

Life Sciences and Clinical Labs tracks

Dedicated conference tracks demonstrate how Proscia is rewiring pathology to reimagine how diagnostic data drives therapeutic decisions.

FOR BIOPHARMA

Transform therapeutic development with real-time pathology intelligence

Hear from biopharma leaders and Proscia’s product team about how Proscia Aperture uncovers diagnostic signals that drive discovery, optimize trial design, accelerate recruitment, and generate evidence for regulatory submissions and label expansions.

See first-hand the speed of diagnosis-driven patient identification, the scale of our global diagnostic network, and the depth of multi-dimensional, AI-enriched data that can fuel your precision medicine portfolio.

Perfect for Biopharma and CRO Leaders in:

Precision Medicine, Therapeutic Disciplines, Clinical Operations, Medical Affairs, CDx, RWE/HEOR, Translation Medicine, Commercial Strategy, Market Access, Clinical Development, Clinical Operations, CDx, RWE/HEOR, Medical Affairs

FOR CLINICAL DIAGNOSTIC LABS

Unlock new revenue potential without changing a single workflow

Clinical leaders and Proscia’s product teams will show you how Proscia Aperture can transform routine pathology diagnoses into real-time insights that broaden patient access to breakthrough therapies — and transform your lab’s economic future.

Labs powered by Concentriq® can elevate pathology’s role in precision medicine by connecting de-identified pathology data to life sciences’ demand. Gain insight into how this model works, what it takes to participate, and what it means for your lab’s long-term growth, competitiveness, and strategic relevance.

Perfect for C-Suite Leaders in:

Clinical Labs, Pathology Groups, Hospital Systems, AMCs, Lab Networks, Medical and Diagnostic Labs

This is your chance to hear from the technology leaders in Proscia’s partner ecosystem about their latest innovations in AI-driven pathology, cloud, and enterprise solutions. This community of established partners are driving digital transformation across diagnostics and drug development. Find out how their solutions support the scaled growth of our customers, drive clinical research opportunities, and deliver on the promise of precision medicine.

PARTNER
SESSION DESCRIPTION
SPEAKER

Cloud ecosystem enabling digital pathology and clinical research

SPEAKER:
Jaron Nix
Senior Product Manager

End-to-end, scalable digital pathology ecosystem from staining to signout

SPEAKER:
Alan Byrne
Principal Global Product Manager, Digital Pathology

Enterprise-scale digital pathology solutions for healthcare systems

SPEAKER:
Svenja Lippok
Head of Digital Pathology & Cardiology IT

AI-driven H&E cancer grading for faster diagnosis and trial inclusion

SPEAKER:
Ben Dobkin
VP, Channel Partnership Sales

AI for consistent, high-quality Breast IHC interpretation

SPEAKER:
Dirk Vossen
Chief Diagnostics Officer

AI precision in PD-L1 scoring to expand trial and therapy access

SPEAKER:
David Mulder
Product Manager

Foundation models revealing new biological insights for research

SPEAKER:
Julie Gerardi
Chief Commercial Officer

Predictive AI biomarker screening to identify at-risk patients

SPEAKER:
Julien Wallemacq
Market Development Director ‑ Diagnostics

AI pathology for skin cancer detection and trial readiness

SPEAKER:
Héloïse Frantz
Head of Sales & Marketing

Register now to see how we’re rewiring pathology to create a smarter, faster future — reimagining how diagnostic data drives therapeutic decisions.

Proscia Aperture surfaces patient insights at the moment of diagnosis to advance discovery and translational research, accelerate trial enrollment, and generate real-time evidence for market access strategies.

EXPLORE PROSCIA APERTURE